Evidence map›Paper›PMID 35623022›Full record

ArticleJCO global oncology2022

Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry.

Don Thiwanka Wijeratne, Sanjeeva Gunasekara, Christopher M Booth, Scott Berry, Matthew Jalink, Laura M Carson, Bishal Gyawali, Hasitha Promod, Umesh Jayarajah, Sanjeewa Seneviratne

Abstract read
In one paragraph

Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Don Thiwanka WijeratneDepartment of Medicine, Queen's University, Kingston, Canada.ORCID 0000-0002-6568-7187
Sanjeeva GunasekaraNational Cancer Institute, Maharagama, Sri Lanka.ORCID 0000-0002-4043-559X
Christopher M BoothDepartment of Oncology, Queen's University, Kingston, Canada.ORCID 0000-0002-1353-3653
Scott BerryDepartment of Oncology, Queen's University, Kingston, Canada.ORCID 0000-0002-1453-7584
Matthew JalinkDivision of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.ORCID 0000-0002-2269-8521
Laura M CarsonDivision of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.ORCID 0000-0002-8425-1477
Bishal GyawaliDepartment of Oncology, Queen's University, Kingston, Canada.ORCID 0000-0001-7444-8594
Hasitha PromodHealth Information Unit, Ministry of Health, Colombo, Sri Lanka.
Umesh JayarajahDepartment of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.ORCID 0000-0002-0398-5197
Sanjeewa SeneviratneDepartment of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.ORCID 0000-0003-0310-1387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer (CRC) ranks among the top five incident cancers in Sri Lanka (SL). Here, we describe disease characteristics and treatment patterns of patients with CRC in SL.

methodsAll adult patients (age > 18 years) diagnosed with CRC during 2016-2020 were identified from the National Cancer Institute SL cancer registry. Cancer stage at diagnosis was defined according to the seventh edition of the TNM staging system. Concordance between recommendations for adjuvant therapy and actual rates of delivery was also analyzed. Descriptive statistics were used to describe the study cohort and treatment patterns.

resultsA total of 1,578 patients were diagnosed with CRC during the study period, 53% (n = 830) with colon cancer and 47% (n = 748) with rectal cancer. Mean age was 61 (range, 18-91) years. Stage distribution was 13%, 28%, 46%, and 12% for stage I, II, III, and IV cancers, respectively. Adjuvant chemotherapy was delivered to 82% of patients with stage III colon cancer. There was a lack of concordance with delivery of neoadjuvant chemoradiotherapy, which was only delivered to 50% of patients with stage III rectal cancer for whom this treatment was indicated.

conclusionAging population and advanced stage of CRC at diagnosis will continue to challenge the provision of high-quality CRC care in SL. Further quantitative and qualitative research may help better understand the nonconcordance with treatment guidelines. Such information would help ease the burden of advanced-stage CRC in SL.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsAdultAgedHospitalsHumansMiddle AgedRegistriesSri Lanka

Identifiers

PMID35623022
PMCPMC9225678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.